
The article examines the use of next-generation sequencing (NGS) and molecular classifier assays in three head and neck cancer (HNC) cases. These advanced technologies improved diagnostic accuracy, distinguishing metastatic disease from second primary malignancies (SPM), thereby optimizing treatment strategies.
Like
Save
Share